December 19, 2016
Matt Richtel and Andrew Pollack
Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrun’s fortune.
Dr. Belldegrun, a physician, co-founded Kite Pharma, a company that could be the first to market next year with a highly anticipated new immunotherapy treatment. But even without a product, Dr. Belldegrun has struck gold.
His stock in Kite is worth about $170 million. Investors have profited along with him, as the company’s share price has soared to about $50 from an initial price of $17 in 2014.